Diagnosis and classification of autoimmune hemolytic anemia

Bass, Garrett; Tuscano, Emily; Tuscano, Joseph M.

doi:10.1016/j.autrev.2013.11.010

Cited by 113 publications

(109 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7 & Cold AIHA is usually caused by IgM antibodies (cold agglutinins) that bind to erythrocyte antigens and also fix and activate complement (including C3) at temperatures below 37.0°C (99.0°F). 7 & Warm AIHA is caused by IgG antibodies that bind to erythrocyte Rh antigens at 37.0°C (99.0°F), usually without complement binding. 7 …”

Section: Key Learning Pointsmentioning

confidence: 99%

See 1 more Smart Citation

Look No Further: An Exercise in Clinical Reasoning

et al. 2016

View full text Add to dashboard Cite

Section: Key Learning Pointsmentioning

confidence: 99%

“…7 & Warm AIHA is caused by IgG antibodies that bind to erythrocyte Rh antigens at 37.0°C (99.0°F), usually without complement binding. 7 …”

Section: Key Learning Pointsmentioning

confidence: 99%

Look No Further: An Exercise in Clinical Reasoning

et al. 2016

View full text Add to dashboard Cite

“…The preliminary laboratory results showed an acute severe anemia and the initial immune-hematological study (Table 1) suggested an autoimmune hemolytic anemia. Therefore, anemia etiological study was added, while other causes of anemia were excluded (Table 2) [6]. For life saving purposes, three more ECs (Erythrocyte concentrates) were compatibilized.…”

Section: Clinical Casementioning

confidence: 99%

Immune Complex Formation Involving Etoricoxib in a Patient with Acute Severe Anemia

Domingues¹,

Teixeira²,

Rocha³

et al. 2017

JPP

View full text Add to dashboard Cite

Abstract:Background: DIIHA (Drug-induced immune hemolytic anemia) is rare, and a specialized laboratory is often required to provide optimal serological tests to confirm diagnosis. There have been few cases reported of etoricoxib-induced immune hemolytic anemia. Immune complexes formed between some drugs and their respective antibodies attach weakly or strongly in a nonspecific way to RBCs (red blood cells). The bound immune complex activates complement, which may lead to hemolysis in vivo. Aims: Demonstration of immune complex formation involving etoricoxib in vitro.Methods: A 46-year-old woman developed acute severe anemia one day after a single dose of etoricoxib 90 mg per os with a strong positive DAT (direct anti-globulin test) and a weak positive IAT (indirect anti-globuline test). For investigation diagnosis, we used the American Association of Blood Banks Technical Manual protocol using patient serum collected in three different moments (at patient admission, one month after and one month after stopping steroids). Results: The authors found strong positive IAT reactions when the patient serum was tested with the drug. Conclusions: The strong agglutination that occurred in the mixture of the drug and the patient serum indicates a drug/antidrug interaction and may lead to DIIHA. This was the first case reported in Portugal of DIIHA induced by etoricoxib.

show abstract

“…Secondary CAD is typically due to a lymphoproliferative diseases such as lymphoma and CLL, or infections such as infectious mononucleosis, mycoplasma pneumonia, cytomegalovirus and varicella zoster. [11,12,14]. Solid tumors including: pulmonary squamous cell carcinoma, metastatic colonic adenocarcinoma, metastatic adrenal adenocarcinoma, basal cell carcinoma may also be associated with secondary CAD [12].…”

Section: Introductionmentioning

confidence: 99%